PALO
ALTO, Calif., May 3, 2023
/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a
commercial-stage biopharmaceutical company focused
on the development of innovative therapies for hepatitis
delta virus (HDV) and other serious diseases, today
reported that, in connection with the appointment of James A. Vollins as General Counsel, Chief
Compliance Officer and Corporate Secretary, Eiger granted him a
stock option to purchase 120,000 shares of Eiger's common stock.
The stock option was approved by the Compensation Committee of
Eiger's Board of Directors and granted under the Eiger
BioPharmaceuticals, Inc. 2021 Inducement Plan, as amended, with a
grant date of April 30, 2023, as an
inducement material to Mr. Vollins entering into employment with
Eiger, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock option vests over four years, with 25 percent vesting
on the first anniversary of the vesting commencement date for Mr.
Vollins and the remainder vesting in 36 equal installments over the
following three years, subject to Mr. Vollins being continuously
employed by Eiger as of such vesting dates. The stock option has a
ten-year term and an exercise price of $1.03, the closing sales price of Eiger's common
stock as reported by Nasdaq on April 28,
2023, which is the trading day preceding the grant date.
Eiger is providing this information in accordance with Nasdaq
Listing Rule 5635(c)(4).
About Eiger
Eiger is a commercial-stage biopharmaceutical company focused on
the development of innovative therapies for hepatitis delta virus
(HDV) and other serious rare diseases. The Eiger HDV platform
includes two first-in- class therapies in Phase 3 that target
critical host processes involved in viral replication. All five
Eiger rare disease programs have been granted FDA breakthrough
therapy designation.
For additional information about Eiger and its clinical programs,
please visit www.eigerbio.com.
Investors:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
Media:
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-301815166.html
SOURCE Eiger BioPharmaceuticals, Inc.
